ID,Class of Spike-Binding Protein,Spike-Binding Protein,Barnes Class,Chains (If Combination),Complex Name,Resolution,Title,Released,DOI,Notes
6W41,Antibody,CR3022,4,,6W41_1,3.084,Crystal structure of SARS-CoV-2 receptor binding domain in complex with human antibody CR3022,3/25/2020,10.1126/science.abb7269,
6WPS,Antibody,S309,3,,6WPS_1;6WPS_2;6WPS_3,"3.1, 3.1",Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment,5/27/2020,10.1038/s41586-020-2349-y,
6WPT,Antibody,S309,3,,6WPT_1;6WPT_2,"3.7, 3.7",Structure of the SARS-CoV-2 spike glycoprotein in complex with the S309 neutralizing antibody Fab fragment (open state),5/27/2020,10.1038/s41586-020-2349-y,
6XC2,Antibody,CC12.1,1,,6XC2_1;6XC2_2,3.112,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1,7/8/2020,10.1126/science.abd2321,
6XC3,Antibody,CC12.1,1,"A,B",6XC3_1,2.698,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022,7/8/2020,10.1126/science.abd2321,
6XC3,Antibody,CR3022,4,"H,L",6XC3_2,2.698,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022,7/8/2020,10.1126/science.abd2321,
6XC4,Antibody,CC12.3,1,,6XC4_1;6XC4_2,2.341,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3,7/8/2020,10.1126/science.abd2321,
6XC7,Antibody,CC12.3,1,"C,D",6XC7_1,2.883,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022,7/8/2020,10.1126/science.abd2321,
6XC7,Antibody,CR3022,4,"H,L",6XC7_2,2.883,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022,7/8/2020,10.1126/science.abd2321,
6XCM,Antibody,C105,1,,6XCM_1;6XCM_2,3.42,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 1),7/1/2020,10.1016/j.cell.2020.06.025,
6XCN,Antibody,C105,1,,6XCN_1;6XCN_2;6XCN_3,3.66,Structure of the SARS-CoV-2 spike glycoprotein in complex with the C105 neutralizing antibody Fab fragment (state 2),7/1/2020,10.1016/j.cell.2020.06.025,
6XDG,Antibody,REGN10933,1,"B,D",6XDG_1,3.9,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies,6/24/2020,10.1126/science.abd0827,class disagreement (2)
6XDG,Antibody,REGN10987,3,"A,C",6XDG_2,3.9,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of two neutralizing antibodies,6/24/2020,10.1126/science.abd0827,
6XE1,Antibody,CV30,1,,6XE1_1,2.75,"Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a potent neutralizing antibody, CV30 Fab",7/1/2020,10.1101/2020.06.12.148692,
6XEY,Antibody,4-Feb,,,6XEY_1;6XEY_2;6XEY_3,3.25,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-4,7/22/2020,10.1038/s41586-020-2571-7,
6XKP,Antibody,CV07-270,3,,6XKP_1;6XKP_2,2.72,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-270,10/14/2020,10.1016/j.cell.2020.09.049,
6XKQ,Antibody,CV07-250,2,,6XKQ_1,2.55,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CV07-250,10/14/2020,10.1016/j.cell.2020.09.049,
6YLA,Antibody,CR3022,4,,6YLA_1;6YLA_2,2.42,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab,4/15/2020,10.1016/j.chom.2020.06.010,
6YM0,Antibody,CR3022,4,,6YM0_1,4.36,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with CR3022 Fab (crystal form 1),4/29/2020,10.1016/j.chom.2020.06.010,
6YOR,Antibody,CR3022,4,,6YOR_1;6YOR_2,"3.3, 3.9",Structure of the SARS-CoV-2 spike S1 protein in complex with CR3022 Fab,4/29/2020,10.1016/j.chom.2020.06.010,
6YZ5,Nanobody/Sybody,H11-D4,2,,6YZ5_1,1.8,H11-D4 complex with SARS-CoV-2 RBD,6/3/2020,,
6YZ7,Antibody,CR3022,4,"BBB,CCC,HHH,LLL",6YZ7_1;6YZ7_2,3.3,"H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex",6/3/2020,,
6YZ7,Nanobody/Sybody,H11-D4,2,"DDD,FFF",6YZ7_3;6YZ7_4,3.3,"H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex",6/3/2020,,
6Z2M,Antibody,CR3022,4,"B,C,H,L",6Z2M_1;6Z2M_3,2.71,"H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex",6/3/2020,,
6Z2M,Nanobody/Sybody,H11-D4,2,"D,F",6Z2M_2;6Z2M_4,2.71,"H11-D4, SARS-CoV-2 RBD, CR3022 ternary complex",6/3/2020,,
6Z43,Nanobody/Sybody,H11-D4,2,,6Z43_1;6Z43_2;6Z43_3,3.3,Cryo-EM Structure of SARS-CoV-2 Spike : H11-D4 Nanobody Complex,6/3/2020,,
6ZBP,Nanobody/Sybody,H11-H4,2,,6ZBP_1,1.85,H11-H4 complex with SARS-CoV-2,7/29/2020,,
6ZCZ,Antibody,EY6A,4,"H,L",6ZCZ_2,2.65,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody.,6/24/2020,10.1038/s41594-020-0480-y,Mutant Spike
6ZCZ,Nanobody/Sybody,H11-H4,2,F,6ZCZ_1,2.65,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in ternary complex with EY6A Fab and a nanobody.,6/24/2020,10.1038/s41594-020-0480-y,Mutant Spike
6ZDG,Antibody,EY6A,4,,6ZDG_1;6ZDG_2;6ZDG_3,4.7,Association of three complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,7/29/2020,10.1038/s41594-020-0480-y,
6ZDH,Antibody,EY6A,4,,6ZDH_1;6ZDH_2;6ZDH_3,3.7,SARS-CoV-2 Spike glycoprotein in complex with a neutralizing antibody EY6A Fab,7/1/2020,10.1038/s41594-020-0480-y,
6ZER,Antibody,EY6A,4,,6ZER_1;6ZER_2;6ZER_3,3.8,Crystal structure of receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with EY6A Fab,6/24/2020,10.1038/s41594-020-0480-y,
6ZFO,Antibody,EY6A,4,,6ZFO_1;6ZFO_2,4.4,Association of two complexes of largely structurally disordered Spike ectodomain with bound EY6A Fab,7/8/2020,10.1038/s41594-020-0480-y,
6ZH9,Antibody,CR3022,4,"HHH,LLL",6ZH9_1,3.31,Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2),9/2/2020,10.1038/s41594-020-0469-6,
6ZH9,Nanobody/Sybody,H11-H4,2,FFF,6ZH9_2,3.31,Ternary complex CR3022 H11-H4 and RBD (SARS-CoV-2),9/2/2020,10.1038/s41594-020-0469-6,
6ZHD,Nanobody/Sybody,H11-H4,2,,6ZHD_1;6ZHD_2;6ZHD_3,"3.7, 3.7",H11-H4 bound to Spike,7/29/2020,,
6ZLR,Antibody,CR3022,4,,6ZLR_1;6ZLR_2;6ZLR_3,3.1,Soaking competent crystal form of the SARS-CoV-2 Receptor Binding Domain (RBD):CR3022 complex.,12/23/2020,10.3389/fphar.2020.615211,
6ZXN,Nanobody/Sybody,Ty1,2,,6ZXN_1;6ZXN_2;6ZXN_3,2.93,Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing nanobodies (Ty1),9/23/2020,10.1038/s41467-020-18174-5,
7A25,Nanobody/Sybody,Sb23,2,,7A25_1;7A25_2;7A25_3,3.06,Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23),11/25/2020,10.1038/s41467-020-19204-y,
7A29,Nanobody/Sybody,Sb23,2,,7A29_1;7A29_2;7A29_3,2.94,Cryo-EM structure of the SARS-CoV-2 spike protein bound to neutralizing sybodies (Sb23) 2-up conformation,10/21/2020,10.1038/s41467-020-19204-y,
7A5R,Antibody,CR3022,4,,7A5R_1;7A5R_2,3.7,Complex of SARS-CoV-2 spike and CR3022 Fab (Non-Uniform Refinement),9/16/2020,10.1038/s41467-020-19146-5,
7A5S,Antibody,CR3022,4,,7A5S_1;7A5S_2,3.9,Complex of SARS-CoV-2 spike and CR3022 Fab (Homogeneous Refinement),9/16/2020,10.1038/s41467-020-19146-5,
7AKD,Antibody,47D11,3,,7AKD_1;7AKD_2,4,Structure of the SARS-CoV-2 spike glycoprotein in complex with the 47D11 neutralizing antibody Fab fragment,5/19/2021,10.1126/sciadv.abf5632,
7B14,Nanobody/Sybody,VHH E,1,,7B14_1,3.79,Nanobody E bound to Spike-RBD in a localized reconstruction,4/28/2021,10.1126/science.abe6230,
7B17,Nanobody/Sybody,VHH VE,,,7B17_1;7B17_2,4.01,SARS-CoV-spike RBD bound to two neutralising nanobodies.,2/10/2021,10.1126/science.abe6230,
7B18,Nanobody/Sybody,VHH VE,,,7B18_1;7B18_2;7B18_3;7B18_4;7B18_5;7B18_6,2.62,SARS-CoV-spike bound to two neutralising nanobodies,4/28/2021,10.1126/science.abe6230,
7B27,Nanobody/Sybody,NM1230,3,,7B27_1;7B27_2,2.902,RBD domain SARS-CoV2 in complex with neutralizing nanobody NM1230,5/12/2021,10.15252/embr.202052325,
7B3O,Antibody,STE90-C11,1,,7B3O_1,2,Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab,12/16/2020,10.1016/j.celrep.2021.109433,
7BEH,Antibody,COVOX-316,,,7BEH_1,2.3,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7BEI,Antibody,COVOX-150,,,7BEI_1,2.3,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7BEJ,Antibody,COVOX-158,,,7BEJ_1,2.42,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 1),3/3/2021,10.1016/j.cell.2021.02.032,
7BEK,Antibody,COVOX-158,,,7BEK_1,2.04,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-158 Fab (crystal form 2),3/3/2021,10.1016/j.cell.2021.02.032,
7BEL,Antibody,COVOX-45,3,"A,B,C,D",7BEL_2;7BEL_3,2.53,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike
7BEL,Antibody,COVOX-88,,"E,F,H,L",7BEL_1;7BEL_4,2.53,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-88 and COVOX-45 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike
7BEM,Antibody,COVOX-269,,,7BEM_1,2.52,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 scFv,3/3/2021,10.1016/j.cell.2021.02.032,
7BEN,Antibody,COVOX-253,1,"D,F,H,L",7BEN_2;7BEN_3,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike; class disagreement (2)
7BEN,Antibody,COVOX-75,,"A,B,G,I",7BEN_1;7BEN_4,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253 and COVOX-75 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike
7BEO,Antibody,COVOX-253H55L,,"C,D,H,L",7BEO_1;7BEO_4,3.19,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike
7BEO,Antibody,COVOX-75,,"A,B,E,F",7BEO_2;7BEO_3,3.19,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-253H55L and COVOX-75 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike
7BEP,Antibody,COVOX-384,,"A,B,D,F",7BEP_2;7BEP_3,2.61,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike
7BEP,Antibody,S309,3,"G,I,H,L",7BEP_1;7BEP_4,2.61,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in a ternary complex with COVOX-384 and S309 Fabs,3/3/2021,10.1016/j.cell.2021.02.032,Mutant Spike
7BNV,Antibody,ION-300,,,7BNV_1,2.35,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-300,11/17/2021,10.3389/fimmu.2021.678570,
7BWJ,Antibody,P2B-2F6,3,,7BWJ_1,2.85,crystal structure of SARS-CoV-2 antibody with RBD,6/3/2020,10.1038/s41586-020-2380-z,
7BYR,Antibody,BD23,,,7BYR_1,3.84,BD23-Fab in complex with the S ectodomain trimer,6/10/2020,10.1016/j.cell.2020.05.025,
7BZ5,Antibody,B38,1,,7BZ5_1,1.84,Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody,5/13/2020,10.1126/science.abc2241,
7C01,Antibody,CB6,1,,7C01_1;7C01_2,2.88,Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD,5/27/2020,10.1038/s41586-020-2381-y,
7C2L,Antibody,4A8,,,7C2L_1;7C2L_2;7C2L_3,3.1,S protein of SARS-CoV-2 in complex bound with 4A8,7/1/2020,10.1126/science.abc6952,
7C53,Other,EK1,,,X,2.278,Crystal Structure of SARS-CoV-2 HR1 motif in complex with pan-CoVs inhibitor EK1,5/19/2021,10.1038/s41392-021-00712-2,"Fusion Peptide, binder?"
7C8V,Nanobody/Sybody,SR4,2,,7C8V_1,2.15,Structure of sybody SR4 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD),6/24/2020,,
7C8W,Nanobody/Sybody,MR17,2,,7C8W_1,2.77,Structure of sybody MR17 in complex with the SARS-CoV-2 S receptor-binding domain (RBD),6/24/2020,,
7CAC,Antibody,H014,4,,7CAC_1,3.55,SARS-CoV-2 S trimer with one RBD in the open state and complexed with one H014 Fab.,2/24/2021,10.1126/science.abc5881,
7CAH,Antibody,H014,4,,7CAH_1,3.9,The interface of H014 Fab binds to SARS-CoV-2 S,8/12/2020,10.1126/science.abc5881,
7CAI,Antibody,H014,4,,7CAI_1;7CAI_2,3.49,SARS-CoV-2 S trimer with two RBDs in the open state and complexed with two H014 Fab,9/23/2020,10.1126/science.abc5881,
7CAK,Antibody,H014,4,,7CAK_1;7CAK_2;7CAK_3,3.58,SARS-CoV-2 S trimer with three RBD in the open state and complexed with three H014 Fab,9/23/2020,10.1126/science.abc5881,
7CAN,Nanobody/Sybody,MR17-K99Y,2,,7CAN_1,2.94,Structure of sybody MR17-K99Y in complex with the SARS-CoV-2 S Receptor-binding domain (RBD),6/24/2020,,
7CDI,Antibody,P2C-1F11,1,,7CDI_1,2.96,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with RBD,11/18/2020,10.1038/s41467-020-20501-9,
7CDJ,Antibody,P2C-1A3,2,,7CDJ_1,3.396,Crystal structure of SARS-CoV-2 antibody P2C-1A3 with RBD,11/18/2020,10.1038/s41467-020-20501-9,
7CH4,Antibody,BD-604,1,,7CH4_1,3.15,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-604 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CH5,Antibody,BD-629,,,7CH5_1,2.7,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHB,Antibody,BD-236,,,7CHB_1,2.4,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHC,Antibody,BD-368-2,2,"A,B",7CHC_2,2.71,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHC,Antibody,BD-629,,"H,L",7CHC_1,2.71,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-629 Fab and BD-368-2 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHE,Antibody,BD-236,,"H,L",7CHE_1,3.416,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHE,Antibody,BD-368-2,2,"A,B",7CHE_2,3.416,Crystal structure of the SARS-CoV-2 RBD in complex with BD-236 Fab and BD-368-2 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHF,Antibody,BD-368-2,2,"A,B",7CHF_1,2.674,Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHF,Antibody,BD-604,1,"H,L",7CHF_2,2.674,Crystal structure of the SARS-CoV-2 RBD in complex with BD-604 Fab and BD-368-2 Fab,9/16/2020,10.1016/j.cell.2020.09.035,
7CHH,Antibody,BD-368-2,2,,7CHH_1;7CHH_2;7CHH_3,3.49,Cryo-EM structure of the SARS-CoV-2 S-6P in complex with BD-368-2 Fabs,9/16/2020,10.1016/j.cell.2020.09.035,
7CHO,Antibody,P5A-1D2,1,,7CHO_1;7CHO_2,2.561,Crystal structure of SARS-CoV-2 antibody P5A-1D2 with RBD,5/19/2021,10.1038/s41467-021-24514-w,
7CHP,Antibody,P5A-3C8,1,,7CHP_1,2.357,Crystal structure of SARS-CoV-2 antibody P5A-3C8 with RBD,5/19/2021,10.1038/s41467-021-24514-w,
7CHS,Antibody,P22A-1D1,1,,7CHS_1,2.401,Crystal structure of SARS-CoV-2 antibody P22A-1D1 with RBD,5/19/2021,10.1038/s41467-021-24514-w,
7CJF,Antibody,P4A1,1,,7CJF_1,2.108,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody Fab,11/11/2020,10.1038/s41467-021-22926-2,
7CM4,Antibody,CT-P59,2,,7CM4_1,2.71,Crystal Structure of COVID-19 virus spike receptor-binding domain complexed with a neutralizing antibody CT-P59,1/20/2021,10.1038/s41467-020-20602-5,
7CWL,Antibody,P17,2,,7CWL_1;7CWL_2;7CWL_3,3.8,SARS-CoV-2 spike protein and P17 fab complex with one RBD in close state,1/27/2021,10.1038/s41422-020-00444-y,
7CWM,Antibody,P17,2,,7CWM_1;7CWM_2;7CWM_3,3.6,Complex of SARS-CoV-2 spike protein and Fab P17 with one RBD in open state and two RBD in closed state,12/16/2020,10.1038/s41422-020-00444-y,
7CWN,Antibody,H014,4,"D,E,M,H,N,O",7CWN_2;7CWN_4;7CWN_5,3.2,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,10.1038/s41422-020-00444-y,
7CWN,Antibody,P17,2,"F,G,I,K,J,L",7CWN_1;7CWN_3;7CWN_6,3.2,P17-H014 Fab cocktail in complex with SARS-CoV-2 spike protein,12/16/2020,10.1038/s41422-020-00444-y,
7CWO,Antibody,P17,2,,7CWO_1,3.9,SARS-CoV-2 spike protein RBD and P17 fab complex,12/16/2020,10.1038/s41422-020-00444-y,
7CWS,Antibody,FC05,,"C,L,K,M,N,P",7CWS_1;7CWS_4;7CWS_5,3.4,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,10.1038/s41422-020-00446-w,
7CWS,Antibody,H014,4,"D,E,F,G,H,I",7CWS_2;7CWS_3;7CWS_6,3.4,SARS-CoV-2 Spike Proteins Trimer in Complex with FC05 and H014 Fabs Cocktail,12/16/2020,10.1038/s41422-020-00446-w,
7CWT,Antibody,FC05,,"H,K,L,M,N,P",7CWT_1;7CWT_3;7CWT_6,3.7,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,10.1038/s41422-020-00446-w,
7CWT,Antibody,HB27,2,"D,E,F,G,I,J",7CWT_2;7CWT_4;7CWT_5,3.7,SARS-CoV-2 Spike protein in complex with hb27 and fc05 Fab cocktail,6/23/2021,10.1038/s41422-020-00446-w,
7CWU,Antibody,FC05,,"F,G,I,J,N,P",7CWU_1;7CWU_3;7CWU_5,3.5,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,10.1038/s41422-020-00446-w,
7CWU,Antibody,P17,2,"H,L,M,O,R,S",7CWU_2;7CWU_4;7CWU_6,3.5,SARS-CoV-2 spike proteins trimer in complex with P17 and FC05 Fabs cocktail,12/16/2020,10.1038/s41422-020-00446-w,
7CYH,Antibody,HB27,2,,7CYH_1,3.9,Binding interface of SARS-CoV-2 RBD and its neutralizing antibody HB27,6/9/2021,,
7CYP,Antibody,HB27,2,,7CYP_1;7CYP_2;7CYP_3,3.5,Complex of SARS-CoV-2 spike trimer with its neutralizing antibody HB27,6/9/2021,,
7CYV,Antibody,FD20,,,7CYV_1,3.13,"Crystal structure of FD20, a neutralizing single-chain variable fragment (scFv) in complex with SARS-CoV-2 Spike receptor-binding domain (RBD)",9/15/2021,,
7CZP,Antibody,P2B-1A1,2,,7CZP_1;7CZP_2,3,S protein of SARS-CoV-2 in complex bound with P2B-1A1,3/10/2021,10.1038/s41422-021-00487-9,
7CZQ,Antibody,P2B-1A10,1,,7CZQ_1;7CZQ_2,2.8,S protein of SARS-CoV-2 in complex bound with P2B-1A10,3/10/2021,10.1038/s41422-021-00487-9,
7CZR,Antibody,P5A-1B8_2B,1,,7CZR_1;7CZR_2,3.5,S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B,3/10/2021,10.1038/s41422-021-00487-9,
7CZS,Antibody,P5A-1B8_3B,1,,7CZS_1;7CZS_2;7CZS_3,3.6,S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B,3/10/2021,10.1038/s41422-021-00487-9,
7CZT,Antibody,P5A-2G9,2,,7CZT_1;7CZT_2,2.7,S protein of SARS-CoV-2 in complex bound with P5A-2G9,3/10/2021,10.1038/s41422-021-00487-9,
7CZU,Antibody,P5A-1B6_2B,2,,7CZU_1;7CZU_2,3.4,S protein of SARS-CoV-2 in complex bound with P5A-1B6_2B,3/10/2021,10.1038/s41422-021-00487-9,
7CZV,Antibody,P5A-1B6_3B,2,,7CZV_1;7CZV_2;7CZV_3,3.3,S protein of SARS-CoV-2 in complex bound with P5A-1B6_3B,3/10/2021,10.1038/s41422-021-00487-9,
7CZW,Antibody,P5A-2G7,,,7CZW_1;7CZW_2,2.8,S protein of SARS-CoV-2 in complex bound with P5A-2G7,3/10/2021,10.1038/s41422-021-00487-9,
7CZX,Antibody,P5A-1B9,2,,7CZX_1;7CZX_2;7CZX_3,2.8,S protein of SARS-CoV-2 in complex bound with P5A-1B9,3/10/2021,10.1038/s41422-021-00487-9,
7CZY,Antibody,P5A-2F11_2B,2,,7CZY_1;7CZY_2,3.3,S protein of SARS-CoV-2 in complex bound with P5A-2F11_2B,3/10/2021,10.1038/s41422-021-00487-9,
7CZZ,Antibody,P5A-2F11_3B,2,,7CZZ_1;7CZZ_2;7CZZ_3,3.2,S protein of SARS-CoV-2 in complex bound with P5A-2F11_3B,3/10/2021,10.1038/s41422-021-00487-9,
7D00,Antibody,FabP5A-1B8,,,7D00_1;7D00_2,3,S protein of SARS-CoV-2 in complex bound with FabP5A-1B8,3/10/2021,10.1038/s41422-021-00487-9,
7D03,Antibody,FabP5A-2G7,,,7D03_1,3.2,S protein of SARS-CoV-2 in complex bound with FabP5A-2G7,3/10/2021,10.1038/s41422-021-00487-9,
7D0B,Antibody,P5A-3C12_1B,2,,7D0B_1,3.9,S protein of SARS-CoV-2 in complex bound with P5A-3C12_1B,3/10/2021,10.1038/s41422-021-00487-9,
7D0C,Antibody,P5A-3A1,1,,7D0C_1;7D0C_2,3.4,S protein of SARS-CoV-2 in complex bound with P5A-3A1,3/10/2021,10.1038/s41422-021-00487-9,
7D0D,Antibody,P5A-3C12_2B,2,,7D0D_1;7D0D_2,3.8,S protein of SARS-CoV-2 in complex bound with P5A-3C12_2B,3/10/2021,10.1038/s41422-021-00487-9,
7D2Z,Nanobody/Sybody,SR31,4,,7D2Z_1,1.97,Structure of sybody SR31 in complex with the SARS-CoV-2 S Receptor Binding domain (RBD),2/17/2021,10.1371/journal.ppat.1009328,
7D30,Nanobody/Sybody,MR17-SR31,2,,7D30_1;7D30_2,2.1,Structure of sybody MR17-SR31 fusion in complex with the SARS-CoV-2 S Receptor Binding domain (RBD),2/17/2021,10.1371/journal.ppat.1009328,
7D4G,Antibody,FC05,,,7D4G_1,3.9,A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2,4/7/2021,,
7D6I,Antibody,GH12,,,7D6I_1,3.41,A neutralizing MAb targeting receptor-binding-domain of SARS-CoV-2,10/13/2021,,
7DCC,Antibody,3C1,2,,7DCC_1;7DCC_2;7DCC_3,4.3,"S-3C1-F3b structure, all the three RBDs are in the up conformation and each of them associates with a 3C1 Fab",12/2/2020,10.1038/s41467-020-20465-w,
7DCX,Antibody,3C1,2,,7DCX_1;7DCX_2;7DCX_3,5.9,"S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.",12/2/2020,10.1038/s41467-020-20465-w,
7DD2,Antibody,3C1,2,,7DD2_1;7DD2_2,5.6,"S-3C1-F2 structure, two RBDs are up and one RBD is down, the two up RBD bind with a 3C1 fab.",12/2/2020,10.1038/s41467-020-20465-w,
7DD8,Antibody,3C1,2,,7DD8_1,7.5,"S-3C1-F1 structure, one RBD is up and two RBDs are down, the up RBD binds with a 3C1 fab",12/2/2020,10.1038/s41467-020-20465-w,
7DEO,Antibody,PR1077,,,7DEO_1;7DEO_2,2.5,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,10.1371/journal.pbio.3001209,
7DET,Antibody,PR961,,,7DET_1;7DET_2,2.2,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,10.1371/journal.pbio.3001209,
7DEU,Antibody,PR953,,,7DEU_1,2.1,Crystal structure of SARS-CoV-2 RBD in complex with a neutralizing antibody scFv,3/31/2021,10.1371/journal.pbio.3001209,
7DJZ,Antibody,MW01,2,,7DJZ_1,2.397,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW01 Fab,6/9/2021,,
7DK0,Antibody,MW05,2,,7DK0_1,3.199,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW05 Fab,6/9/2021,,
7DK4,Antibody,2H2,2,,7DK4_1;7DK4_2;7DK4_3,3.8,"S-2H2-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 2H2 Fab.",12/2/2020,10.1038/s41467-020-20465-w,
7DK5,Antibody,2H2,2,,7DK5_1,13.5,"S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab",12/2/2020,10.1038/s41467-020-20465-w,
7DK6,Antibody,2H2,2,,7DK6_1;7DK6_2,4.3,"S-2H2-F2 structure, two RBDs are up and one RBD is down, each up RBD binds with a 2H2 Fab.",12/2/2020,10.1038/s41467-020-20465-w,
7DK7,Antibody,2H2,2,,7DK7_1;7DK7_2;7DK7_3,9.7,"S-2H2-F3b structure, three RBDs are up and each RBD binds with a 2H2 Fab.",12/2/2020,10.1038/s41467-020-20465-w,
7DPM,Antibody,MW06,4,,7DPM_1;7DPM_2;7DPM_3;7DPM_4,3.304,Crystal structure of SARS-CoV-2 Spike RBD in complex with MW06 Fab,2/17/2021,10.1080/19420862.2021.1953683,
7DX4,Antibody,FC08,3,,7DX4_1,3.6,The structure of FC08 Fab-hA.CE2-RBD complex,4/21/2021,,
7DZX,Antibody,8D2,,,7DZX_1,3.53,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 8D2,6/2/2021,10.1016/j.cell.2021.05.032,
7DZY,Antibody,2490,,,7DZY_1;7DZY_2;7DZY_3,3.6,Spike protein from SARS-CoV2 with Fab fragment of enhancing antibody 2490,6/2/2021,10.1016/j.cell.2021.05.032,
7.00E+23,Antibody,CA521,2,,7E23_1,3.3,SARS-CoV-2 spike in complex with the CA521 neutralizing antibody Fab (focused refinement on Fab-RBD),5/5/2021,10.1038/s42003-021-02029-w,
7.00E+39,Antibody,Ab4,,,7E39_1,3.7,SARS-CoV-2 spike in complex with the Ab4 neutralizing antibody (State 3),9/1/2021,10.1038/s41421-021-00292-z,
7E3B,Antibody,Ab5,,,7E3B_1,4.2,SARS-Cov-2 spike in complex with the Ab5 neutralizing antibody (focused refinement on Fab-RBD),9/1/2021,10.1038/s41421-021-00292-z,
7E3C,Antibody,Ab1,,,7E3C_1,4.2,SARS-CoV-2 spike in complex with the Ab1 neutralizing antibody (focused refinement on Fab-RBD),9/1/2021,10.1038/s41421-021-00292-z,
7E3K,Antibody,13G9,2,,7E3K_1;7E3K_2;7E3K_3,3.9,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,,
7E3L,Antibody,58G6,2,,7E3L_1;7E3L_2;7E3L_3,3.6,Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants,9/15/2021,,
7E3O,Antibody,nCoV617,,,7E3O_1,2.51,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody nCoV617,9/15/2021,,
7E5O,Antibody,NT-193,,,7E5O_1,2.8,Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193,9/8/2021,,
7E5R,Antibody,FC05,,"Q,P,R,S,W,X",7E5R_2;7E5R_4;7E5R_9,"3.6, 3.6",SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,10.1038/s41422-021-00497-7,Mutant Spike
7E5R,Antibody,H014,4,"D,E,H,L,N,O",7E5R_1;7E5R_5;7E5R_7,"3.6, 3.6",SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,10.1038/s41422-021-00497-7,Mutant Spike
7E5R,Antibody,P17,2,"I,K,M,T,U,V",7E5R_3;7E5R_6;7E5R_8,"3.6, 3.6",SARS-CoV-2 S trimer with three-antibody cocktail complex,10/13/2021,10.1038/s41422-021-00497-7,Mutant Spike
7E5S,Antibody,FC05,,"N,Q,P,S,U,V",7E5S_2;7E5S_3;7E5S_6,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,10.1038/s41422-021-00497-7,Mutant Spike
7E5S,Antibody,H014,4,"D,E,H,L",7E5S_5;7E5S_7,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,10.1038/s41422-021-00497-7,Mutant Spike
7E5S,Antibody,HB27,2,"O,R",7E5S_1,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,10.1038/s41422-021-00497-7,Mutant Spike
7E5S,Antibody,P17,2,"I,J,K,T",7E5S_4;7E5S_8,"3.6, 3.6",SARS-CoV-2 S trimer with four-antibody cocktail complex,11/17/2021,10.1038/s41422-021-00497-7,Mutant Spike
7E5Y,Antibody,2B11,1,,7E5Y_1;7E5Y_2,3.59,Molecular basis for neutralizing antibody 2B11 targeting SARS-CoV-2 RBD,6/23/2021,,
7E7X,Antibody,N11,,,7E7X_1;7E7X_2,2.78,SARS-CoV-2 Spike Protein N terminal domain in Complex with N11 Fab,6/9/2021,10.1038/s41422-021-00514-9,
7E7Y,Antibody,BD-623,2,,7E7Y_1;7E7Y_2,2.41,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-623 Fab,6/9/2021,10.1038/s41422-021-00514-9,
7.00E+86,Antibody,BD-508,,,7E86_1,2.9,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-508 Fab,6/9/2021,10.1038/s41422-021-00514-9,
7.00E+88,Antibody,BD-515,,,7E88_1;7E88_2;7E88_3;7E88_4,3.14,Crystal structure of the SARS-CoV-2 S RBD in complex with BD-515 Fab,6/9/2021,10.1038/s41422-021-00514-9,
7E8C,Antibody,604,,"D,E,N,O,P,Q",7E8C_3;7E8C_5;7E8C_7,3.16,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,10.1038/s41422-021-00514-9,Mutant Spike
7E8C,Antibody,368-2,,"a,I,J,K,M,Z",7E8C_1;7E8C_4;7E8C_8,3.16,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,10.1038/s41422-021-00514-9,Mutant Spike
7E8C,Antibody,N9,,"H,L,S,T,U,V",7E8C_2;7E8C_6;7E8C_9,3.16,SARS-CoV-2 S-6P in complex with 9 Fabs,6/9/2021,10.1038/s41422-021-00514-9,Mutant Spike
7E8F,Antibody,N9,,,7E8F_1;7E8F_2;7E8F_3,3.18,SARS-CoV-2 NTD in complex with N9 Fab,6/9/2021,10.1038/s41422-021-00514-9,
7E8M,Antibody,P2C-1F11,1,,7E8M_1,2.09,Crystal structure of SARS-CoV-2 antibody P2C-1F11 with mutated RBD,5/26/2021,,Mutated RBD
7EAM,Antibody,7D6,3,,7EAM_1;7EAM_2,1.4,immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 7D6,3/17/2021,,
7EAN,Antibody,6D6,3,,7EAN_1,1.91,immune complex of SARS-CoV-2 RBD and cross-neutralizing antibody 6D6,3/31/2021,10.1038/s41467-021-25997-3,
7EH5,Antibody,RBD-chAb15,4,"D,E,F,O,P,Q",7EH5_2;7EH5_3;7EH5_5,4,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,10.1038/s41594-021-00652-z,
7EH5,Antibody,RBD-chAb45,,"H,I,J,L,M,N",7EH5_1;7EH5_4;7EH5_6,4,"Cryo-EM structure of SARS-CoV-2 S-D614G variant in complex with neutralizing antibodies, RBD-chAb15 and RBD-chAb45",9/1/2021,10.1038/s41594-021-00652-z,
7EJ4,Antibody,RBD-chAb-25,,,7EJ4_1;7EJ4_2;7EJ4_3,3.6,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-25,6/23/2021,,
7EJ5,Antibody,RBD-chAb-45,,,7EJ5_1;7EJ5_2;7EJ5_3,3.5,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody RBD-chAb-45,6/23/2021,,
7EY0,Antibody,BD-744,3,"A,B",7EY0_2,3.2,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab,9/8/2021,10.1038/s41422-021-00555-0,
7EY0,Antibody,BD-813,1,"H,L",7EY0_1,3.2,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-813 Fab and BD-744 Fab,9/8/2021,10.1038/s41422-021-00555-0,
7EY4,Antibody,BD-667,3,,7EY4_1,"3.69, 3.69",Local CryoEM of the SARS-CoV-2 S6PV2 in complex with BD-667,9/8/2021,10.1038/s41422-021-00555-0,
7EY5,Antibody,BD-771,2,"H,L",7EY5_2,3.4,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab,9/8/2021,10.1038/s41422-021-00555-0,
7EY5,Antibody,BD-821,3,"B,C",7EY5_1,3.4,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-771 Fab and BD-821 Fab,9/8/2021,10.1038/s41422-021-00555-0,
7EYA,Antibody,BD-804,3,,7EYA_1,3.77,Local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-804 Fab,9/8/2021,10.1038/s41422-021-00555-0,
7EZV,Antibody,BD-812,3,,7EZV_1;7EZV_2,3.3,local CryoEM structure of the SARS-CoV-2 S6PV2 in complex with BD-812 Fab and BD-836 Fab,9/8/2021,10.1038/s41422-021-00555-0,
7F62,Antibody,chAb-25,,,7F62_1,3.6,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-25 (Focused refinement of S-RBD and chAb-25 region),8/4/2021,,
7F63,Antibody,chAb-45,,,7F63_1,3.9,Cryo-EM structure of SARS-CoV-2 spike in complex with a neutralizing antibody chAb-45 (Focused refinement of S-RBD and chAb-45 region),8/4/2021,,
7FG2,Nanobody/Sybody,K-874A VHH,,,7FG2_1,4.4,"Minor cryo-EM structure of S protein trimer of SARS-CoV2 with K-874A VHH, composite map",9/29/2021,,
7FG3,Nanobody/Sybody,K-874 VHH,,,7FG3_1,3.9,"Major cryo-EM structure of S protein trimer of SARS-CoV2 with K-874, composite map",9/29/2021,,
7JMO,Antibody,COVA2-04,1,,7JMO_1,2.359,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-04,8/26/2020,10.1101/2020.07.26.222232,
7JMP,Antibody,COVA2-39,2,,7JMP_1,1.712,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody COVA2-39,8/26/2020,10.1101/2020.07.26.222232,
7JMW,Antibody,COVA1-16,4,,7JMW_1,2.89,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with cross-neutralizing antibody COVA1-16 Fab,10/14/2020,10.1101/2020.08.02.233536,
7JV2,Antibody,S2H13,2,,7JV2_1,3.5,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody Fab fragment (local refinement of the receptor-binding motif and Fab variable domains),10/14/2020,10.1016/j.cell.2020.09.037,
7JV4,Antibody,S2H13,2,,7JV4_1;7JV4_2;7JV4_3,3.4,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (one RBD open),10/14/2020,10.1016/j.cell.2020.09.037,
7JV6,Antibody,S2H13,2,,7JV6_1;7JV6_2;7JV6_3,3,SARS-CoV-2 spike in complex with the S2H13 neutralizing antibody (closed conformation),10/14/2020,10.1016/j.cell.2020.09.037,
7JVA,Antibody,S2A4,4,,7JVA_1,3.6,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment (local refinement of the receptor-binding domain and Fab variable domains),10/14/2020,10.1016/j.cell.2020.09.037,
7JVB,Nanobody/Sybody,Nb20,2,,7JVB_1;7JVB_2,3.287,Crystal structure of the SARS-CoV-2 spike receptor-binding domain (RBD) with nanobody Nb20,12/2/2020,10.1126/science.abe4747,
7JVC,Antibody,S2A4,4,,7JVC_1;7JVC_2;7JVC_3,3.3,SARS-CoV-2 spike in complex with the S2A4 neutralizing antibody Fab fragment,10/14/2020,10.1016/j.cell.2020.09.037,
7JW0,Antibody,S304,4,,7JW0_1;7JW0_2;7JW0_3,4.3,SARS-CoV-2 spike in complex with the S304 neutralizing antibody Fab fragment,10/14/2020,10.1016/j.cell.2020.09.037,
7JWB,Nanobody/Sybody,VH3 B01,,,7JWB_1;7JWB_2;7JWB_3,"6, 3.2",SARS CoV2 Spike ectodomain with engineered trimerized VH binder,10/7/2020,10.1038/s41589-020-00679-1,Not referred to as nanboody but seems like human-derived nanobody.
7JX3,Antibody,S2H14,2,"C,D",7JX3_1,2.65,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,10/14/2020,10.1016/j.cell.2020.09.037,
7JX3,Antibody,S304,4,"H,L",7JX3_3,2.65,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,10/14/2020,10.1016/j.cell.2020.09.037,
7JX3,Antibody,S309,3,"A,B",7JX3_2,2.65,Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology,10/14/2020,10.1016/j.cell.2020.09.037,
7JZL,Other,LCB1,2,,7JZL_1;7JZL_2;7JZL_3,2.7,SARS-CoV-2 spike in complex with LCB1 (2RBDs open),9/23/2020,10.1126/science.abd9909,Protein Inhibitor
7JZM,Other,LCB3,2,,7JZM_1,3.5,SARS-CoV-2 spike in complex with LCB3 (local refinement of the RBD and LCB3),9/23/2020,10.1126/science.abd9909,Protein Inhibitor
7JZN,Other,LCB3,2,,7JZN_1;7JZN_2;7JZN_3,3.1,SARS-CoV-2 spike in complex with LCB3 (2RBDs open),9/23/2020,10.1126/science.abd9909,Protein Inhibitor
7JZU,Other,LCB1,2,,7JZU_1,3.1,SARS-CoV-2 spike in complex with LCB1 (local refinement of the RBD and LCB1),9/23/2020,10.1126/science.abd9909,Protein Inhibitor
7K43,Antibody,S2M11,2,,7K43_1;7K43_2;7K43_3,2.6,SARS-CoV-2 spike in complex with the S2M11 neutralizing antibody Fab fragment,10/7/2020,10.1126/science.abe3354,
7K45,Antibody,S2E12,1,,7K45_1,3.7,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment (local refinement of the RBD and Fab variable domains),10/7/2020,10.1126/science.abe3354,
7K4N,Antibody,S2E12,1,,7K4N_1;7K4N_2;7K4N_3,3.3,SARS-CoV-2 spike in complex with the S2E12 neutralizing antibody Fab fragment,10/7/2020,10.1126/science.abe3354,
7K8M,Antibody,C102,1,,7K8M_1,3.2,"Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C102",10/21/2020,10.1038/s41586-020-2852-1,
7K8S,Antibody,C002,2,,7K8S_1;7K8S_2;7K8S_3,3.4,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C002 (state 1)",10/21/2020,10.1038/s41586-020-2852-1,
7K8T,Antibody,C002,2,,7K8T_1;7K8T_2;7K8T_3,3.4,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C002 (State 2)",10/21/2020,10.1038/s41586-020-2852-1,
7K8U,Antibody,C104,2,,7K8U_1,3.8,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C104",10/21/2020,10.1038/s41586-020-2852-1,
7K8V,Antibody,C110,3,,7K8V_1;7K8V_2,3.8,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C110",10/21/2020,10.1038/s41586-020-2852-1,
7K8W,Antibody,C119,3,,7K8W_1;7K8W_2,3.6,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C119",10/21/2020,10.1038/s41586-020-2852-1,
7K8X,Antibody,C121,2,,7K8X_1;7K8X_2,"3.9, 3.9","Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 1)",10/21/2020,10.1038/s41586-020-2852-1,
7K8Y,Antibody,C121,2,,7K8Y_1,"4.4, 4.4","Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C121 (State 2)",10/21/2020,10.1038/s41586-020-2852-1,
7K8Z,Antibody,C135,3,,7K8Z_1;7K8Z_2,3.5,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, C135",10/21/2020,10.1038/s41586-020-2852-1,
7K90,Antibody,C144,2,,7K90_1;7K90_2;7K90_3,3.24,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, C144",10/21/2020,10.1038/s41586-020-2852-1,
7K9H,Antibody,2B04,2,,7K9H_1;7K9H_2,3.2,"SARS-CoV-2 Spike in complex with neutralizing Fab 2B04 (one up, two down conformation)",9/29/2021,10.1016/j.celrep.2021.109881,
7K9I,Antibody,2B04,2,,7K9I_1,3.3,SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2B04 (local refinement),9/29/2021,10.1016/j.celrep.2021.109881,
7K9J,Antibody,2H04,3,,7K9J_1;7K9J_2;7K9J_3,3,SARS-CoV-2 Spike in complex with neutralizing Fab 2H04 (three down conformation),9/29/2021,10.1016/j.celrep.2021.109881,
7K9K,Antibody,2H04,3,,7K9K_1,3.14,SARS-CoV-2 Spike RBD in complex with neutralizing Fab 2H04 (local refinement),9/29/2021,10.1016/j.celrep.2021.109881,
7K9Z,Antibody,52,3,"H,L",7K9Z_1,2.95,Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52,10/28/2020,10.1038/s41467-021-23825-2,
7K9Z,Antibody,298,2,"A,B",7K9Z_2,2.95,Crystal structure of SARS-CoV-2 receptor binding domain in complex with the Fab fragments of neutralizing antibodies 298 and 52,10/28/2020,10.1038/s41467-021-23825-2,
7KFV,Antibody,C1A-B12,1,,7KFV_1;7KFV_2;7KFV_3,2.102,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B12 Fab),12/2/2020,10.1101/2020.11.13.381533,
7KFW,Antibody,C1A-B3,1,,7KFW_1;7KFW_2;7KFW_3,2.792,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-B3 Fab),12/2/2020,10.1101/2020.11.13.381533,
7KFX,Antibody,C1A-C2,1,,7KFX_1,2.226,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-C2 Fab),12/2/2020,10.1101/2020.11.13.381533,
7KFY,Antibody,C1A-F10,1,,7KFY_1,2.157,Structural basis for a germline-biased antibody response to SARS-CoV-2 (RBD:C1A-F10 Fab),12/2/2020,10.1101/2020.11.13.381533,
7KGJ,Nanobody/Sybody,Sb45,2,,7KGJ_1,2.3,Crystal structure of synthetic nanobody (Sb45) complexes with SARS-CoV-2 receptor binding domain,2/3/2021,10.1016/j.jbc.2021.101202,
7KGK,Nanobody/Sybody,Sb16,,,7KGK_1,2.6,Crystal structure of synthetic nanobody (Sb16) complexes with SARS-CoV-2 receptor binding domain,2/3/2021,10.1016/j.jbc.2021.101202,
7KKK,Antibody,Nb6,2,,7KKK_1;7KKK_2;7KKK_3,3.03,SARS-CoV-2 Spike in complex with neutralizing nanobody Nb6,11/11/2020,10.1126/science.abe3255,
7KKL,Antibody,mNb6,2,,7KKL_1;7KKL_2;7KKL_3,2.85,SARS-CoV-2 Spike in complex with neutralizing nanobody mNb6,11/11/2020,10.1126/science.abe3255,
7KL9,Other,CTC-445.2,,,7KL9_1;7KL9_2;7KL9_3,4.1,"Structure of the SARS-CoV-2 S 6P trimer in complex with the ACE2 protein decoy, CTC-445.2 (State 4)",11/11/2020,10.1126/science.abe0075,
7KLG,Antibody,15033,2,,7KLG_1;7KLG_2,3.2,SARS-CoV-2 RBD in complex with Fab 15033,2/10/2021,10.1016/j.jmb.2021.167177,
7KLH,Antibody,15033-7,2,,7KLH_1;7KLH_2,3,SARS-CoV-2 RBD in complex with Fab 15033-7,2/10/2021,10.1016/j.jmb.2021.167177,
7KLW,Nanobody/Sybody,Sb45,2,B,7KLW_2,2.6,Crystal structure of synthetic nanobody (Sb45+Sb68) complexes with SARS-CoV-2 receptor binding domain,2/3/2021,10.1016/j.jbc.2021.101202,
7KLW,Nanobody/Sybody,Sb68,,C,7KLW_1,2.6,Crystal structure of synthetic nanobody (Sb45+Sb68) complexes with SARS-CoV-2 receptor binding domain,2/3/2021,10.1016/j.jbc.2021.101202,
7KM5,Nanobody/Sybody,Nanosota-1,,,7KM5_1;7KM5_2,3.19,Crystal structure of SARS-CoV-2 RBD complexed with Nanosota-1,8/4/2021,,
7KMG,Antibody,LY-CoV555,2,,7KMG_1;7KMG_2,2.16,LY-CoV555 neutralizing antibody against SARS-CoV-2,1/27/2021,10.1126/scitranslmed.abf1906,
7KMH,Antibody,LY-CoV488,1,,7KMH_1,1.72,LY-CoV488 neutralizing antibody against SARS-CoV-2,1/27/2021,10.1126/scitranslmed.abf1906,
7KMI,Antibody,LY-CoV481,1,,7KMI_1,1.73,LY-CoV481 neutralizing antibody against SARS-CoV-2,1/27/2021,10.1126/scitranslmed.abf1906,
7KMK,Antibody,15033-7,2,,7KMK_1;7KMK_2,4.2,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, two RBDs bound",2/10/2021,10.1016/j.jmb.2021.167177,
7KML,Antibody,15033-7,2,,7KML_1;7KML_2;7KML_3,3.8,"cryo-EM structure of SARS-CoV-2 spike in complex with Fab 15033-7, three RBDs bound",2/10/2021,10.1016/j.jmb.2021.167177,
7KN3,Antibody,S-B8,,,7KN3_1;7KN3_2,2.251,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-B8 Fab,9/22/2021,10.1002/advs.202102181,
7KN4,Antibody,S-E6,,,7KN4_1;7KN4_2,2.7,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain complexed with a pre-pandemic antibody S-E6 Fab,9/22/2021,10.1002/advs.202102181,
7KN5,Nanobody/Sybody,VHH E,1,"C,D",7KN5_1;7KN5_4,1.87,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobodies VHH E and U,1/20/2021,10.1126/science.abe6230,
7KN5,Nanobody/Sybody,VHH U,,"E,F",7KN5_2;7KN5_3,1.87,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobodies VHH E and U,1/20/2021,10.1126/science.abe6230,
7KN6,Antibody,CC12.3,1,"H,L",7KN6_1,2.55,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody Fab CC12.3,1/20/2021,10.1126/science.abe6230,
7KN6,Nanobody/Sybody,VHH V,,C,7KN6_2,2.55,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH V and antibody Fab CC12.3,1/20/2021,10.1126/science.abe6230,
7KN7,Antibody,CC12.3,1,"H,L",7KN7_1,2.73,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody Fab CC12.3,1/20/2021,10.1126/science.abe6230,
7KN7,Nanobody/Sybody,VHH W,,B,7KN7_2,2.73,Crystal structure of SARS-CoV-2 receptor binding domain complexed with nanobody VHH W and antibody Fab CC12.3,1/20/2021,10.1126/science.abe6230,
7KQE,Antibody,3D11,1,,7KQE_1;7KQE_2;7KQE_3,2.88,SARS-CoV-2 spike glycoprotein:Fab 3D11 complex,5/26/2021,10.1016/j.cell.2021.04.033,
7KS9,Antibody,910-30,1,,7KS9_1,4.75,Cryo-EM structure of prefusion SARS-CoV-2 spike glycoprotein in complex with 910-30 Fab,2/10/2021,10.1101/2020.12.31.424987,
7KSG,Nanobody/Sybody,VHH E,1,,7KSG_1;7KSG_2;7KSG_3,3.33,SARS-CoV-2 spike in complex with nanobodies E,1/20/2021,10.1126/science.abe6230,
7KXJ,Antibody,15033-7,2,,7KXJ_1;7KXJ_2;7KXJ_3,6.4,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 3-""up"", asymmetric",2/3/2021,10.1016/j.jmb.2021.167177,
7KXK,Antibody,15033-7,2,,7KXK_1;7KXK_2;7KXK_3,5,"SARS-CoV-2 spike protein in complex with Fab 15033-7, 2-""up""-1-""down"" conformation",2/3/2021,10.1016/j.jmb.2021.167177,
7KZB,Antibody,CR3014-C8,4,"H,L",7KZB_2,2.83,Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies,2/3/2021,10.1080/19420862.2021.1922134,
7KZB,Antibody,CR3022-B6,2,"A,B",7KZB_1,2.83,Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1antibodies,2/3/2021,10.1080/19420862.2021.1922134,
7L02,Antibody,2G12,,,7L02_1,3.2,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to one copy of domain-swapped antibody 2G12,12/30/2020,10.1016/j.cell.2021.04.042,
7L06,Antibody,2G12,,,7L06_1;7L06_2,3.3,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound to two copies of domain-swapped antibody 2G12,12/30/2020,10.1016/j.cell.2021.04.042,
7L09,Antibody,2G12,,,7L09_1,3.1,Cryo-EM structure of SARS-CoV-2 2P S ectodomain bound domain-swapped antibody 2G12 from masked 3D refinement,12/30/2020,10.1016/j.cell.2021.04.042,
7L0N,Antibody,S304,4,"H,L,M,N",7L0N_2;7L0N_3,2.78,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2/17/2021,10.1016/j.cell.2021.01.037,Mutant Spike; ACE2 Included
7L0N,Antibody,S309,3,"A,B,C,D",7L0N_1;7L0N_4,2.78,Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity,2/17/2021,10.1016/j.cell.2021.01.037,
7L2C,Antibody,15-Feb,,,7L2C_1;7L2C_2,3.65,Crystallographic structure of neutralizing antibody 2-51 in complex with SARS-CoV-2 spike N-terminal domain (NTD),2/10/2021,10.1016/j.chom.2021.03.005,
7L2D,Antibody,Jan-87,,,7L2D_1,3.55,Cryo-EM structure of NTD-directed neutralizing antibody 1-87 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,10.1016/j.chom.2021.03.005,
7L2E,Antibody,18-Apr,,,7L2E_1;7L2E_2;7L2E_3,2.97,Cryo-EM structure of NTD-directed neutralizing antibody 4-18 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,10.1016/j.chom.2021.03.005,
7L2F,Antibody,24-May,,,7L2F_1;7L2F_2;7L2F_3,3.9,Cryo-EM structure of NTD-directed neutralizing antibody 5-24 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/24/2021,10.1016/j.chom.2021.03.005,
7L3N,Antibody,LY-CoV555,2,,7L3N_1,3.27,SARS-CoV 2 Spike Protein bound to LY-CoV555,2/3/2021,10.1101/2020.09.30.318972,
7L56,Antibody,Feb-43,,,7L56_1;7L56_2;7L56_3,3.6,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43,4/14/2021,10.1016/j.celrep.2021.108950,
7L57,Antibody,15-Feb,,,7L57_1,5.87,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-15,4/14/2021,10.1016/j.celrep.2021.108950,
7L58,Antibody,H4,2,,7L58_1,5.07,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4,4/14/2021,10.1016/j.celrep.2021.108950,
7L5B,Antibody,15-Feb,,,7L5B_1,3.18,Crystallographic structure of neutralizing antibody 2-15 in complex with SARS-CoV-2 spike receptor-binding Domain (RBD).,2/10/2021,10.1016/j.celrep.2021.108950,
7L7D,Antibody,AZD8895,,,7L7D_1,2.5,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibody AZD8895,9/1/2021,,
7L7E,Antibody,AZD1061,,"C,D,E,F,M,N,O,P",7L7E_1;7L7E_4;7L7E_6;7L7E_8,3,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,,
7L7E,Antibody,AZD8895,,"A,B,H,I,J,L,T,U",7L7E_2;7L7E_3;7L7E_5;7L7E_7,3,Crystal structure of SARS-CoV-2 spike RBD in complex with human monoclonal antibodies AZD8895 and AZD1061,9/1/2021,,
7LAA,Antibody,DH1041,2,,7LAA_1,3.42,Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1041,3/17/2021,10.1016/j.cell.2021.06.021,
7LAB,Antibody,DH1052,,,7LAB_1;7LAB_2;7LAB_3,"2.97, 2.97",Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1052,3/10/2021,10.1016/j.cell.2021.06.021,
7LCN,Antibody,DH1050.1,,,7LCN_1;7LCN_2;7LCN_3,"3.35, 3.35",Structure of SARS-CoV-2 S protein in complex with N-terminal domain antibody DH1050.1,1/27/2021,10.1016/j.cell.2021.06.021,
7LD1,Antibody,DH1047,4,,7LD1_1;7LD1_2;7LD1_3,"3.4, 3.4",Structure of SARS-CoV-2 S protein in complex with Receptor Binding Domain antibody DH1047,1/27/2021,10.1016/j.cell.2021.06.021,
7LDJ,Nanobody/Sybody,WNb-2,2,,7LDJ_1;7LDJ_2;7LDJ_3;7LDJ_4,2.36,SARS-CoV-2 receptor binding domain in complex with WNb-2,5/5/2021,,
7LJR,Antibody,DH1043,2,,7LJR_1,3.66,SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab,3/31/2021,10.1101/2020.12.31.424729,
7LM8,Antibody,COVA1-16,4,"H,L",7LM8_1,1.936,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neutralizing antibodies CV38-142 and COVA1-16 Fabs isolated from COVID-19 patients,3/31/2021,10.1101/2021.02.11.430866,
7LM8,Antibody,CV38-142,3,"M,N",7LM8_2,1.936,Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with two cross-neutralizing antibodies CV38-142 and COVA1-16 Fabs isolated from COVID-19 patients,3/31/2021,10.1101/2021.02.11.430866,
7LOP,Antibody,CR3022,4,"B,C,W,V",7LOP_1;7LOP_3,2.246,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,3/3/2021,10.1126/science.abh1139,
7LOP,Antibody,CV05-163,2,"H,L,X,Y",7LOP_2;7LOP_4,2.246,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV05-163 and CR3022,3/3/2021,10.1126/science.abh1139,
7LQ7,Antibody,COVA1-16,4,"P,Q,T,U,y,z",7LQ7_2;7LQ7_3;7LQ7_5,3.4,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,,
7LQ7,Antibody,CV503,,"C,D,F,G,H,L",7LQ7_1;7LQ7_4;7LQ7_6,3.4,Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CV503 and COVA1-16,9/15/2021,,
7LQV,Antibody,8-Apr,,,7LQV_1;7LQV_2;7LQV_3,3.25,Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike,3/24/2021,,
7LQW,Antibody,17-Feb,,,7LQW_1,4.47,Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spike,3/24/2021,10.1016/j.chom.2021.03.005,
7LRS,Antibody,A23-58.1,1,,7LRS_1,3.89,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,7/14/2021,10.1126/science.abh1766,class disagreement (2)
7LRT,Antibody,A23-58.1,1,,7LRT_1;7LRT_2;7LRT_3,3.54,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody A23-58.1 that targets the receptor-binding domain,7/14/2021,10.1126/science.abh1766,class disagreement (2)
7LS9,Antibody,Jan-57,,,7LS9_1;7LS9_2;7LS9_3,3.42,Cryo-EM structure of neutralizing antibody 1-57 in complex with prefusion SARS-CoV-2 spike glycoprotein,3/17/2021,10.1016/j.str.2021.05.014,
7LSS,Antibody,7-Feb,,,7LSS_1,3.72,Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7,3/17/2021,10.1016/j.str.2021.05.014,
7LX5,Nanobody/Sybody,WNb 10,,A,7LX5_1,3.44,The SARS-CoV-2 spike protein receptor binding domain bound to neutralizing nanobodies WNb 2 and WNb 10,5/5/2021,10.1073/pnas.2101918118,
7LX5,Nanobody/Sybody,WNb 2,,C,7LX5_2,3.44,The SARS-CoV-2 spike protein receptor binding domain bound to neutralizing nanobodies WNb 2 and WNb 10,5/5/2021,10.1073/pnas.2101918118,
7LXW,Antibody,S2X333,,,7LXW_1,"2.8, 2.8",SARS-CoV-2 S/S2M11/S2X333 Local Refinement,4/14/2021,10.1016/j.cell.2021.03.028,
7LXX,Antibody,S2L28,,,7LXX_1,3,SARS-CoV-2 S/S2M11/S2L28 Local Refinement,4/14/2021,10.1016/j.cell.2021.03.028,
7LXY,Antibody,S2M11,2,"C,D,E,F,K,M",7LXY_1;7LXY_3;7LXY_6,2.2,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,10.1016/j.cell.2021.03.028,Mutant Spike
7LXY,Antibody,S2X333,,"G,H,I,L,N,O",7LXY_2;7LXY_4;7LXY_5,2.2,SARS-CoV-2 S/S2M11/S2X333 Global Refinement,4/14/2021,10.1016/j.cell.2021.03.028,Mutant Spike
7LXZ,Antibody,S2L28,,"G,H,I,J,N,O",7LXZ_1;7LXZ_3;7LXZ_5,2.6,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,10.1016/j.cell.2021.03.028,Mutant Spike
7LXZ,Antibody,S2M11,2,"C,D,E,F,L,M",7LXZ_2;7LXZ_4;7LXZ_6,2.6,SARS-CoV-2 S/S2M11/S2L28 Global Refinement,4/14/2021,10.1016/j.cell.2021.03.028,Mutant Spike
7LY0,Antibody,S2M28,,,7LY0_1,2.6,SARS-CoV-2 S/S2M11/S2M28 Local Refinement,4/14/2021,10.1016/j.cell.2021.03.028,
7LY2,Antibody,S2M11,2,"C,D,E,F,K,M",7LY2_2;7LY2_3;7LY2_6,2.5,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,10.1016/j.cell.2021.03.028,Mutant Spike
7LY2,Antibody,S2M28,,"G,H,I,L,N,O",7LY2_1;7LY2_4;7LY2_5,2.5,SARS-CoV-2 S/S2M11/S2M28 Global Refinement,4/14/2021,10.1016/j.cell.2021.03.028,Mutant Spike
7LY3,Antibody,S2M28,,,7LY3_1;7LY3_2,3,Crystal structure of SARS-CoV-2 S NTD bound to S2M28 Fab,4/14/2021,10.1016/j.cell.2021.03.028,
7M3I,Antibody,CV2-75,4,,7M3I_1;7M3I_2,2.8,"Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibody, CV2-75 Fab",5/12/2021,10.1016/j.celrep.2021.109353,
7M42,Antibody,REGN10985,4,"C,D",7M42_1,3.3,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989,7/28/2021,10.1016/j.cell.2021.06.002,
7M42,Antibody,REGN10989,2,"A,B",7M42_2,3.3,Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989,7/28/2021,10.1016/j.cell.2021.06.002,
7M53,Antibody,B6,,,X,1.4,B6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide,5/26/2021,10.1038/s41594-021-00596-4,only modeled binding 1147-1156
7M6D,Antibody,BG4-25,1,"H,L",7M6D_2,3.1,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022,5/5/2021,10.1016/j.cell.2021.04.032,
7M6D,Antibody,CR3022,4,"A,B",7M6D_1,3.1,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibodies BG4-25 and CR3022,5/5/2021,10.1016/j.cell.2021.04.032,
7M6E,Antibody,BG10-19,3,,7M6E_1;7M6E_2;7M6E_3,3.3,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG10-19",5/5/2021,10.1016/j.cell.2021.04.032,
7M6F,Antibody,BG1-22,1,,7M6F_1;7M6F_2,3.9,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG1-22",5/5/2021,10.1016/j.cell.2021.04.032,
7M6G,Antibody,BG7-15,3,,7M6G_1;7M6G_2,3.7,"Structure of the SARS-CoV-2 S 6P trimer in complex with the human neutralizing antibody Fab fragment, BG7-15",5/5/2021,10.1016/j.cell.2021.04.032,
7M6H,Antibody,BG7-20,2,,7M6H_1;7M6H_2,4,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG7-20",5/5/2021,10.1016/j.cell.2021.04.032,
7M6I,Antibody,BG1-24,2,,7M6I_1;7M6I_2,4,"Structure of the SARS-CoV-2 S 2P trimer in complex with the human neutralizing antibody Fab fragment, BG1-24",5/5/2021,10.1016/j.cell.2021.04.032,
7M71,Antibody,5A6,,,7M71_1,2.66,SARS-CoV-2 Spike:5A6 Fab complex I focused refinement,5/26/2021,10.1016/j.cell.2021.04.033,
7M7B,Antibody,3D11,1,,7M7B_1,2.95,SARS-CoV-2 Spike:Fab 3D11 complex focused refinement,5/26/2021,10.1016/j.cell.2021.04.033,
7M7W,Antibody,S2H97,3,"C,D,E,F",7M7W_1;7M7W_3,2.65,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,5/5/2021,10.1038/s41586-021-03807-6,
7M7W,Antibody,S2X259,4,"A,B,H,L",7M7W_2;7M7W_4,2.65,Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape,5/5/2021,10.1038/s41586-021-03807-6,
7M8J,Antibody,CM25,,,7M8J_1,3.48,SARS-CoV-2 S-NTD + Fab CM25,5/19/2021,10.1126/science.abg5268,
7MDW,Nanobody/Sybody,Nb105,,B,7MDW_2,3.58,CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb105,8/11/2021,,
7MDW,Nanobody/Sybody,Nb21,2,A,7MDW_1,3.58,CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb105,8/11/2021,,
7ME7,Nanobody/Sybody,Nb105,,B,7ME7_2,3.73,CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb17 and Nb105,8/11/2021,,
7ME7,Nanobody/Sybody,Nb17,4,A,7ME7_1,3.73,CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb17 and Nb105,8/11/2021,,class disagreement (3)
7MEJ,Nanobody/Sybody,Nb21,2,A,7MEJ_1,3.55,CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb36,8/11/2021,,
7MEJ,Nanobody/Sybody,Nb36,,B,7MEJ_2,3.55,CryoEM structure of SARS-CoV-2 RBD in complex with nanobodies Nb21 and Nb36,8/11/2021,,
7MF1,Antibody,47D1,3,,7MF1_1,2.092,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody 47D1,5/12/2021,10.1016/j.celrep.2021.109109,
7MFU,Nanobody/Sybody,Sb14,,"B,E",7MFU_1;7MFU_2,1.7,Crystal structure of synthetic nanobody (Sb14+Sb68) complexes with SARS-CoV-2 receptor binding domain,6/2/2021,10.1016/j.jbc.2021.101202,
7MFU,Nanobody/Sybody,Sb68,,"C,F",7MFU_3;7MFU_4,1.7,Crystal structure of synthetic nanobody (Sb14+Sb68) complexes with SARS-CoV-2 receptor binding domain,6/2/2021,10.1016/j.jbc.2021.101202,
7MJH,Antibody,VH ab8,2,,7MJH_1;7MJH_2;7MJH_3,2.66,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8,5/12/2021,10.1371/journal.pbio.3001237,Mutant Spike
7MJI,Antibody,VH ab8,2,,7MJI_1,2.81,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to VH ab8 (focused refinement of RBD and VH ab8),5/12/2021,10.1371/journal.pbio.3001237,Mutant Spike
7MJJ,Antibody,ab1,,,7MJJ_1;7MJJ_2,3.32,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 1),5/12/2021,10.1371/journal.pbio.3001237,
7MJK,Antibody,ab1,,,7MJK_1;7MJK_2;7MJK_3,2.73,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (class 2),5/12/2021,10.1371/journal.pbio.3001237,
7MJL,Antibody,ab1,,,7MJL_1,2.95,Cryo-EM structure of the SARS-CoV-2 N501Y mutant spike protein ectodomain bound to Fab ab1 (focused refinement of RBD and Fab ab1),5/12/2021,10.1371/journal.pbio.3001237,
7MKL,Antibody,SARS2-38,2,,7MKL_1,3.2,SARS-CoV-2 Spike in complex with neutralizing Fab SARS2-38 (three down conformation),5/12/2021,10.1016/j.immuni.2021.08.016,
7MKM,Antibody,SARS2-38,2,,7MKM_1,3.16,SARS-CoV-2 Spike RBD in complex with neutralizing Fab SARS2-38 (local refinement),5/12/2021,10.1016/j.immuni.2021.08.016,
7MLZ,Antibody,B1-182.1,1,,7MLZ_1,3.71,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain,7/28/2021,10.1126/science.abh1766,class disagreement (2)
7MM0,Antibody,B1-182.1,1,,7MM0_1,3.15,Cryo-EM structure of SARS-CoV-2 spike in complex with neutralizing antibody B1-182.1 that targets the receptor-binding domain,7/28/2021,10.1126/science.abh1766,class disagreement (2)
7MMO,Antibody,LY-CoV1404,3,,7MMO_1;7MMO_2,2.427,LY-CoV1404 neutralizing antibody against SARS-CoV-2,5/12/2021,10.1101/2021.04.30.442182,
7MY2,Nanobody/Sybody,Nb30,4,,7MY2_1;7MY2_2;7MY2_3,2.65,CryoEM structure of neutralizing nanobody Nb30 in complex with SARS-CoV2 spike,6/16/2021,10.1038/s41586-021-03676-z,
7MY3,Nanobody/Sybody,Nb12,3,,7MY3_1;7MY3_2;7MY3_3,2.9,CryoEM structure of neutralizing nanobody Nb12 in complex with SARS-CoV2 spike,6/16/2021,10.1038/s41586-021-03676-z,
7MZF,Antibody,PDI 37,,,7MZF_1,2.493,SARS-CoV-2 receptor binding domain bound to Fab PDI 37,10/6/2021,10.1016/j.celrep.2021.109822,
7MZG,Antibody,PDI 42,,,7MZG_1,2,SARS-CoV-2 receptor binding domain bound to Fab PDI 42,10/6/2021,10.1016/j.celrep.2021.109822,
7MZH,Antibody,WCSL 119,,,7MZH_1;7MZH_2,2.1,SARS-CoV-2 receptor binding domain bound to Fab WCSL 119,10/6/2021,10.1016/j.celrep.2021.109822,
7MZI,Antibody,WCSL 129,1,,7MZI_1,1.85,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129,10/6/2021,10.1016/j.celrep.2021.109822,
7MZJ,Antibody,PDI 93,,"H,L,M,N",7MZJ_2;7MZJ_4,2.4,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,10/6/2021,10.1016/j.celrep.2021.109822,
7MZJ,Antibody,WCSL 129,1,"C,D,E,F",7MZJ_1;7MZJ_3,2.4,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 93,10/6/2021,10.1016/j.celrep.2021.109822,
7MZK,Antibody,PDI 96,,"H,L,M,N",7MZK_1;7MZK_4,2.25,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,10/6/2021,10.1016/j.celrep.2021.109822,
7MZK,Antibody,WCSL 129,1,"C,D,E,F",7MZK_2;7MZK_3,2.25,SARS-CoV-2 receptor binding domain bound to Fab WCSL 129 and Fab PDI 96,10/6/2021,10.1016/j.celrep.2021.109822,
7MZL,Antibody,PDI 210,,,7MZL_1,3.7,SARS-CoV-2 receptor binding domain bound to Fab PDI 210,10/6/2021,10.1016/j.celrep.2021.109822,
7MZM,Antibody,PDI 215,,,7MZM_1,2.3,SARS-CoV-2 receptor binding domain bound to Fab PDI 215,10/6/2021,10.1016/j.celrep.2021.109822,
7MZN,Antibody,PDI 231,,,7MZN_1,3.1,SARS-CoV-2 receptor binding domain bound to Fab PDI 231,10/6/2021,10.1016/j.celrep.2021.109822,
7N0G,Nanobody/Sybody,Sb45,2,,7N0G_1;7N0G_2;7N0G_3,3.02,"CryoEm structure of SARS-CoV-2 spike protein (S-6P, 1-up) in complex with sybodies (Sb45)",6/2/2021,10.1016/j.jbc.2021.101202,
7N0H,Nanobody/Sybody,Sb45,2,,7N0H_1;7N0H_2,3.34,"CryoEM structure of SARS-CoV-2 spike protein (S-6P, 2-up) in complex with sybodies (Sb45)",6/2/2021,10.1016/j.jbc.2021.101202,
7N3I,Antibody,C098,,,7N3I_1,2.03,Crystal structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment C098,8/4/2021,10.1016/j.immuni.2021.07.008,
7N4I,Antibody,WRAIR-2057,,,7N4I_1,2.284,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2057.,10/6/2021,10.1038/s41590-021-01068-z,
7N4J,Antibody,WRAIR-2173,,,7N4J_1,2.207,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2173.,10/6/2021,10.1038/s41590-021-01068-z,
7N4L,Antibody,WRAIR-2125,,,7N4L_1,3.601,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2125.,11/10/2021,10.1038/s41590-021-01068-z,
7N4M,Antibody,WRAIR-2151,,,7N4M_1,3.79,Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing human antibody WRAIR-2151.,11/10/2021,10.1038/s41590-021-01068-z,
7N5H,Antibody,Feb-36,,,7N5H_1;7N5H_2;7N5H_3,3.24,Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein,11/3/2021,10.1101/2021.10.13.464307,
7N62,Antibody,C12C9,,,7N62_1,4,SARS-CoV-2 Spike (2P) in complex with C12C9 Fab (NTD local reconstruction),8/4/2021,10.1101/2021.03.10.434840,
7N64,Antibody,G32R7,3,,7N64_1,4.2,SARS-CoV-2 Spike (2P) in complex with G32R7 Fab (RBD and NTD local reconstruction),8/4/2021,10.1101/2021.03.10.434840,
7N8H,Antibody,S2L20,,"B,C,I,J,N,O",7N8H_2;7N8H_3;7N8H_5,2.3,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,10.1126/science.abi7994,
7N8H,Antibody,S2M11,2,"D,E,G,H,L,M",7N8H_1;7N8H_4;7N8H_6,2.3,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 Global Refinement,7/14/2021,10.1126/science.abi7994,Mutant Spike
7N8I,Antibody,S2L20,,,7N8I_1,3,SARS-CoV-2 S (B.1.429 / epsilon variant) + S2M11 + S2L20 (Local Refinement of the NTD/S2L20),7/14/2021,10.1126/science.abi7994,Mutant Spike
7N9A,Nanobody/Sybody,Nb21,2,,7N9A_1,3.5,Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS RBD with NB21,8/4/2021,,
7N9B,Nanobody/Sybody,Nb21,2,,7N9B_1;7N9B_2,3.8,Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS with NB21,8/4/2021,,"pdb misnumbered, 412 is actually 320"
7N9C,Nanobody/Sybody,Nb95,,,7N9C_1;7N9C_2,3.71,Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS with NB95,8/4/2021,,"pdb misnumbered, 412 is actually 320"
7N9E,Nanobody/Sybody,Nb34,4,,7N9E_1,3.52,Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting novel and conserved epitopes-CovS with NB34,8/4/2021,,
7N9T,Nanobody/Sybody,Nb17,4,,7N9T_1;7N9T_2;7N9T_3,3.18,CryoEM structure of SARS-CoV-2 Spike in complex with Nb17,8/11/2021,,class disagreement (3)
7ND3,Antibody,COVOX-40,1,,7ND3_1,3.7,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7ND4,Antibody,COVOX-88,,,7ND4_1;7ND4_2;7ND4_3,3.6,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-88 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7ND5,Antibody,COVOX-150,,,7ND5_1,3.4,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-150 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7ND6,Antibody,COVOX-40,1,,7ND6_1,7.3,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-40 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7ND7,Antibody,COVOX-316,,,7ND7_1;7ND7_2;7ND7_3,3.6,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-316 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7ND8,Antibody,COVOX-384,,,7ND8_1,3.5,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-384 Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7ND9,Antibody,COVOX-253H55L,,,7ND9_1,2.8,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-253H55L Fab,3/3/2021,,
7NDA,Antibody,COVOX-253H55L,,,7NDA_1,3.3,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-253H55L Fab,3/3/2021,,
7NDB,Antibody,COVOX-253H165L,2,,7NDB_1,4.6,EM structure of SARS-CoV-2 Spike glycoprotein in complex with COVOX-253H165L Fab,3/3/2021,10.1016/j.cell.2021.02.032,
7NDC,Antibody,COVOX-159,,,7NDC_1;7NDC_2;7NDC_3,4.1,EM structure of SARS-CoV-2 Spike glycoprotein (all RBD down) in complex with COVOX-159,3/3/2021,10.1016/j.cell.2021.02.032,
7NDD,Antibody,COVOX-159,,,7NDD_1;7NDD_2;7NDD_3,4.2,EM structure of SARS-CoV-2 Spike glycoprotein (one RBD up) in complex with COVOX-159,3/3/2021,10.1016/j.cell.2021.02.032,
7NEG,Antibody,COVOX-269,,,7NEG_1,2.19,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab,3/3/2021,10.1016/j.cell.2021.02.033,
7NEH,Antibody,COVOX-269,,,7NEH_1,1.77,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-269 Fab,3/3/2021,10.1016/j.cell.2021.02.033,
7NKT,Nanobody/Sybody,NM1226,4,,7NKT_1,2.3,RBD domain of SARS-CoV2 in complex with neutralizing nanobody NM1226,5/12/2021,10.15252/embr.202052325,
7NP1,Antibody,ION-360,,,7NP1_1;7NP1_2;7NP1_3;7NP1_4,2.8,Crystal Structure of the SARS-CoV-2 Receptor Binding Domain in Complex with Antibody ION-360,11/17/2021,10.3389/fimmu.2021.678570,
7NTC,Antibody,P008_056,,,7NTC_1,3.6,Trimeric SARS-CoV-2 spike ectodomain bound to P008_056 Fab,4/28/2021,10.1126/sciadv.abg7607,
7NX6,Antibody,COVOX-222,1,"A,B",7NX6_2,2.25,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,
7NX6,Antibody,EY6A,4,"H,L",7NX6_1,2.25,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,
7NX7,Antibody,COVOX-222,1,"A,B",7NX7_2,2.3,Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NX7,Antibody,EY6A,4,"H,L",7NX7_1,2.3,Crystal structure of the K417N mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NX8,Antibody,COVOX-222,1,"A,B",7NX8_2,1.95,Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NX8,Antibody,EY6A,4,"H,L",7NX8_1,1.95,Crystal structure of the K417T mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NX9,Antibody,COVOX-222,1,"A,B",7NX9_1,2.4,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NX9,Antibody,EY6A,4,"H,L",7NX9_2,2.4,Crystal structure of the N501Y mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NXA,Antibody,COVOX-222,1,"A,B",7NXA_1,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NXA,Antibody,EY6A,4,"H,L",7NXA_2,2.5,Crystal structure of the receptor binding domain of SARS-CoV-2 B.1.351 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NXB,Antibody,COVOX-222,1,"A,B",7NXB_1,2.67,Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7NXB,Antibody,EY6A,4,"H,L",7NXB_2,2.67,Crystal structure of the receptor binding domain of SARS-CoV-2 P.1 variant Spike glycoprotein in complex with COVOX-222 and EY6A Fabs,4/7/2021,10.1016/j.cell.2021.03.055,Mutant Spike
7OAN,Nanobody/Sybody,C5,2,,7OAN_1;7OAN_2;7OAN_3,"3, 3",Nanobody C5 bound to Spike,8/11/2021,10.1038/s41467-021-25480-z,
7OAO,Nanobody/Sybody,C5,2,,7OAO_1,1.5,Nanobody C5 bound to RBD,8/11/2021,10.1038/s41467-021-25480-z,
7OAP,Nanobody/Sybody,C1,,AAA,7OAP_1,1.901,Nanobody H3 AND C1 bound to RBD,8/11/2021,10.1038/s41467-021-25480-z,
7OAP,Nanobody/Sybody,H3,,FFF,7OAP_2,1.901,Nanobody H3 AND C1 bound to RBD,8/11/2021,10.1038/s41467-021-25480-z,
7OAQ,Nanobody/Sybody,H3,,,7OAQ_1;7OAQ_2,1.55,Nanobody H3 AND C1 bound to RBD with Kent mutation,8/11/2021,10.1038/s41467-021-25480-z,Mutant Spike
7OAU,Nanobody/Sybody,C5,2,,7OAU_1;7OAU_2,1.65,Nanobody C5 bound to Kent variant RBD (N501Y),8/11/2021,10.1038/s41467-021-25480-z,Mutant Spike
7OAY,Nanobody/Sybody,F2,,,7OAY_1;7OAY_2;7OAY_3;7OAY_4;7OAY_5;7OAY_6,2.34,Nanobody F2 bound to RBD,8/11/2021,10.1038/s41467-021-25480-z,
7OLZ,Nanobody/Sybody,Re5D06,,C,7OLZ_2,1.75,Crystal structure of the SARS-CoV-2 RBD with neutralizing-VHHs Re5D06 and Re9F06,8/11/2021,10.15252/embj.2021107985,
7OLZ,Nanobody/Sybody,Re9F06,,B,7OLZ_1,1.75,Crystal structure of the SARS-CoV-2 RBD with neutralizing-VHHs Re5D06 and Re9F06,8/11/2021,10.15252/embj.2021107985,
7OR9,Antibody,COVOX-222,1,"A,B",7OR9_2,2.34,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs,7/7/2021,10.1016/j.cell.2021.06.020,
7OR9,Antibody,COVOX-278,,"H,L",7OR9_1,2.34,Crystal structure of the receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-222 and COVOX-278 Fabs,7/7/2021,10.1016/j.cell.2021.06.020,
7ORA,Antibody,COVOX-253,1,"F,G,H,L",7ORA_1;7ORA_4,2.6,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,7/7/2021,10.1016/j.cell.2021.06.020,Mutant Spike; class disagreement (2)
7ORA,Antibody,COVOX-45,3,"A,B,D,E",7ORA_2;7ORA_3,2.6,Crystal structure of the T478K mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-45 and COVOX-253 Fabs,7/7/2021,10.1016/j.cell.2021.06.020,Mutant Spike
7ORB,Antibody,COVOX-253,1,"C,D,H,L",7ORB_1;7ORB_4,2.5,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,7/7/2021,10.1016/j.cell.2021.06.020,Mutant Spike; class disagreement (2)
7ORB,Antibody,COVOX-75,,"A,B,E,F",7ORB_2;7ORB_3,2.5,Crystal structure of the L452R mutant receptor binding domain of SARS-CoV-2 Spike glycoprotein in complex with COVOX-75 and COVOX-253 Fabs,7/7/2021,10.1016/j.cell.2021.06.020,Mutant Spike
7P40,Antibody,P5C3,1,,7P40_1;7P40_2;7P40_3,3.5,P5C3 is a potent fab neutralizer,10/13/2021,10.1016/j.celrep.2021.109814,class disagreement (2)
7P77,Nanobody/Sybody,Sb#15,2,"A,D,H",7P77_1;7P77_2;7P77_6,2.98,SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation,8/4/2021,,Mutant Spike
7P77,Nanobody/Sybody,Sb#68,,"W,X,Y",7P77_3;7P77_4;7P77_5,2.98,SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 3up conformation,8/4/2021,,Mutant Spike
7P78,Nanobody/Sybody,Sb#15,2,"B,D,H",7P78_1;7P78_2;7P78_3,3.32,SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 1up/1up-out/1down conformation,8/4/2021,,Mutant Spike
7P78,Nanobody/Sybody,Sb#68,,"W,Y",7P78_4;7P78_5,3.32,SARS-CoV-2 spike protein in complex with sybody#15 and sybody#68 in a 1up/1up-out/1down conformation,8/4/2021,,Mutant Spike
7P79,Nanobody/Sybody,Sb#15,2,,7P79_1;7P79_2;7P79_3,4,SARS-CoV-2 spike protein in complex with sybodyb#15 in a 1up/1up-out/1down conformation.,8/4/2021,,Mutant Spike
7P7A,Nanobody/Sybody,Sb#68,,,7P7A_1;7P7A_2,4.76,SARS-CoV-2 spike protein in complex with sybody#68 in a 2up/1flexible conformation,8/4/2021,,
7P7B,Nanobody/Sybody,Sb#68,,,X,3.13,SARS-CoV-2 spike protein in complex with sybody#68 in a 1up/2down conformation,8/4/2021,,No binder?
7PHG,Antibody,P5C3,1,,7PHG_1,4.3,MaP OF P5C3RBD Interface,10/13/2021,10.1016/j.celrep.2021.109814,class disagreement (2)
7R6W,Antibody,S2X35,,"H,L",7R6W_2,1.83,SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab,7/21/2021,10.1038/s41586-021-03807-6,
7R6W,Antibody,S309,3,"A,B",7R6W_1,1.83,SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2X35 Fab and S309 Fab,7/21/2021,10.1038/s41586-021-03807-6,
7R6X,Antibody,S2E12,1,"C,D",7R6X_3,2.95,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",7/21/2021,10.1038/s41586-021-03807-6,
7R6X,Antibody,S304,4,"H,L",7R6X_2,2.95,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",7/21/2021,10.1038/s41586-021-03807-6,
7R6X,Antibody,S309,3,"A,B",7R6X_1,2.95,"SARS-CoV-2 spike receptor-binding domain (RBD) in complex with S2E12 Fab, S309 Fab, and S304 Fab",7/21/2021,10.1038/s41586-021-03807-6,
7R7N,Antibody,S2D106,2,,7R7N_1,3.95,SARS-CoV-2 spike in complex with the S2D106 neutralizing antibody Fab fragment (local refinement of the RBD and S2D106),7/21/2021,10.1038/s41586-021-03807-6,
7R8L,Antibody,C099,,"H,L",7R8L_2,2.6,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022,8/4/2021,10.1016/j.immuni.2021.07.008,
7R8L,Antibody,CR3022,4,"C,D",7R8L_1,2.6,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody C099 and CR3022,8/4/2021,10.1016/j.immuni.2021.07.008,
7R8M,Antibody,C032,3,,7R8M_1;7R8M_2,3.4,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C032,8/4/2021,10.1016/j.immuni.2021.07.008,
7R8N,Antibody,C051,2,,7R8N_1;7R8N_2;7R8N_3,3.55,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C051,8/4/2021,10.1016/j.immuni.2021.07.008,
7R8O,Antibody,C548,2,,7R8O_1;7R8O_2;7R8O_3,3.5,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C548,8/4/2021,10.1016/j.immuni.2021.07.008,
7RA8,Antibody,S2X259,4,,7RA8_1;7RA8_2;7RA8_3,3.1,SARS-CoV-2 S glycoprotein in complex with S2X259 Fab,8/4/2021,10.1038/s41586-021-03817-4,
7RAL,Antibody,S2X259,4,,7RAL_1,,SARS-CoV-2 S bound to S2X259 Fab (local refinement of the RBD/S2X259 variable domains),8/4/2021,10.1038/s41586-021-03817-4,
7RKU,Antibody,C022,,,7RKU_1;7RKU_2,3.2,"Structure of the SARS-CoV-2 receptor binding domain in complex with the human neutralizing antibody Fab fragment, C022",9/22/2021,10.1016/j.celrep.2021.109760,
7RKV,Antibody,C118,4,,7RKV_1;7RKV_2;7RKV_3,3.45,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody C118 (State 1),9/22/2021,10.1016/j.celrep.2021.109760,
7RNJ,Antibody,S2P6,,,X,2.67,S2P6 Fab fragment bound to the SARS-CoV/SARS-CoV-2 spike stem helix peptide,8/11/2021,10.1126/science.abj3321,only modeled binding 1146-1160
7RR0,Antibody,PDI 222,,,7RR0_1,3.12,SARS-CoV-2 receptor binding domain bound to Fab PDI 222,10/6/2021,10.1016/j.celrep.2021.109822,
7RW2,Antibody,7-May,,,7RW2_1;7RW2_2;7RW2_3,3.5,Cryo-EM structure of NTD-directed neutralizing antibody 5-7 in complex with prefusion SARS-CoV-2 spike glycoprotein,9/1/2021,10.1101/2021.06.29.450397,
7RXD,Other,Legobody,,,7RXD_1,3.6,CryoEM structure of RBD domain of COVID-19 in complex with Legobody,10/6/2021,10.1073/pnas.2115001118,Nanobody attached to two scaffolds.
7S0B,Antibody,N-612-056,,,7S0B_1;7S0B_2,2.9,Structure of the SARS-CoV-2 RBD in complex with neutralizing antibody N-612-056,10/6/2021,10.1101/2021.09.14.460356,
7S0C,Antibody,N-612-017,3,,7S0C_1;7S0C_2,3.25,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-017,10/6/2021,10.1101/2021.09.14.460356,
7S0D,Antibody,N-612-014,,,7S0D_1;7S0D_2;7S0D_3,3.5,Structure of the SARS-CoV-2 S 6P trimer in complex with neutralizing antibody N-612-014,10/6/2021,10.1101/2021.09.14.460356,
7S0E,Antibody,N-612-004,,,7S0E_1,4.9,Structure of the SARS-CoV-2 S1 subunit in complex with antibody N-612-004,10/6/2021,10.1101/2021.09.14.460356,
7S3N,Antibody,Fab22,,,X,1.9,SARS-CoV-2 S stem helix peptide bound to Fab22,10/27/2021,10.1016/j.celrep.2021.109929,only modeled binding 1147-1156
7S4S,Antibody,CoV11,,,7S4S_1,2.05,Crystal Structure of SARS-CoV-2 S receptor-binding domain (RBD) in complex CoV11 Fab,9/22/2021,,
7SO9,Antibody,S2L20,,"B,C,I,J,N,O",7SO9_2;7SO9_3;7SO9_5,2.4,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SO9,Antibody,S2M11,2,"D,E,G,H,L,M",7SO9_1;7SO9_4;7SO9_6,2.4,SARS-CoV-2 S B.1.617.2 delta variant + S2M11 + S2L20 Global Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SOA,Antibody,S2L20,,,7SOA_1,3.1,SARS-CoV-2 S NTD B.1.617.2 delta variant + S2L20 Local Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SOB,Antibody,S2L20,,"B,C,E,F,L,M",7SOB_2;7SOB_4;7SOB_5,2.4,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SOB,Antibody,S309,3,"G,H,I,J,N,O",7SOB_1;7SOB_3;7SOB_6,2.4,SARS-CoV-2 S B.1.617.1 kappa variant + S309 + S2L20 Global Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SOC,Antibody,S309,3,,7SOC_1,3.3,SARS-CoV-2 S RBD B.1.617.1 kappa variant S309 Local Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SOD,Antibody,S2L20,,,7SOD_1,3.2,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2L20 Local Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SOE,Antibody,S2X303,,,7SOE_1;7SOE_2;7SOE_3,2.8,SARS-CoV-2 S B.1.617.1 kappa variant + S2X303 Global Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7SOF,Antibody,S2X303,,,7SOF_1,3.6,SARS-CoV-2 S NTD B.1.617.1 kappa variant S2X303 Local Refinement,11/17/2021,10.1126/science.abl8506,Mutant Spike
7V26,Antibody,XG005,3,,7V26_1;7V26_2;7V26_3,3.85,XG005-bound SARS-CoV-2 S,10/20/2021,10.1007/s13238-021-00871-6,
7V2A,Antibody,XG014,3,,7V2A_1;7V2A_2;7V2A_3,"3.4, 3.4",SARS-CoV-2 Spike trimer in complex with XG014 Fab,10/20/2021,10.1007/s13238-021-00871-6,
7VMU,Antibody,E4,,,7VMU_1,2.89,Crystal Structure of SARS-CoV Spike Receptor-Binding Domain Complexed with Neutralizing Antibody,11/3/2021,,
7VNB,Nanobody/Sybody,n3113,4,,7VNB_1,2.27,Crystal structure of the SARS-CoV-2 RBD in complex with a human single domain antibody n3113,11/24/2021,10.1038/s41392-021-00810-1,Not referred to as nanboody but seems like human-derived nanobody.
7VNC,Nanobody/Sybody,n3113,4,,7VNC_1,3.7,"Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113 (UDD-state, state 1)",11/24/2021,10.1038/s41392-021-00810-1,Not referred to as nanboody but seems like human-derived nanobody.
7VND,Nanobody/Sybody,n3113,4,,7VND_1;7VND_2,3.6,"Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113 (UUD-state, state 2)",11/24/2021,10.1038/s41392-021-00810-1,Not referred to as nanboody but seems like human-derived nanobody.
7VNE,Nanobody/Sybody,n3113,4,,7VNE_1;7VNE_2;7VNE_3,3.5,Structure of the SARS-CoV-2 spike glycoprotein in complex with a human single domain antibody n3113.1 (UUU-state),11/24/2021,10.1038/s41392-021-00810-1,Not referred to as nanboody but seems like human-derived nanobody.
